Vogenx posts cash-rich Q3 and launches Phase 2b study
Vogenx raised $84.4M from a $93.4M IPO in August 2026 to strengthen its balance sheet with $82.1M in liquidity and initiated its EMERGE clinical trial for mizagliflozin in post-bariatric hypoglycemia.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed